U.S. STOCKS ON THE MOVE-Ford Motor, REX, Weibo
U.S. STOCKS ON THE MOVE-Packaging Corp of America, ImmunoGen, SilverBow Resources
Soligenix rises after FDA clears ulcer drug for mid-stage study
Brief: Soligenix Q3 net income USD -1.7 million
Brief: Soligenix, Inc. Announces Adjournment Of Annual Meeting, Information For Reconvened Annual Meeting
U.S. STOCKS ON THE MOVE-Starbucks, Williams-Sonoma, FedEx
U.S. STOCKS ON THE MOVE-Soligenix, Enovis, Lifeway Foods
Soligenix rises on data from co's Ebola and Marburg vaccine candidates
Brief: Soligenix Inc Files For Mixed Shelf Of Up To $50 Million
Brief: Soligenix Announces Expansion Of SGX302 Phase 2A Study
Brief: Soligenix Gets Notice From Nasdaq That Co Is Not In Compliance With Minimum Bid Price Requirement
Brief: Soligenix Receives Letter From Nasdaq Confirming Compliance For Listing On Nasdaq
Brief: Soligenix Announces European Patent Grant For Use Of Dusquetide In Oral Mucositis
Soligenix Inc reports results for the quarter ended in March - Earnings Summary
Brief: Soligenix Inc Says Qtrly Net Loss Was $0.36 Per Share
Brief: Soligenix Announces Scheduling Of Type A Meeting With U.S. FDA
Brief: Soligenix Announces Closing Of $8.5 Million Public Offering
Soligenix Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Soligenix Announces Pricing Of $8.5 Million Public Offering